Protalix BioTherapeutics, Inc.
PLX
$1.93
$0.021.05%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 52.74M | 61.84M | 61.95M | 59.76M | 53.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.74M | 61.84M | 61.95M | 59.76M | 53.40M |
| Cost of Revenue | 45.88M | 38.64M | 38.69M | 42.28M | 36.70M |
| Gross Profit | 6.86M | 23.20M | 23.26M | 17.49M | 16.70M |
| SG&A Expenses | 11.68M | 11.16M | 10.82M | 11.68M | 12.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.24M | 55.47M | 53.72M | 55.14M | 49.48M |
| Operating Income | -5.50M | 6.37M | 8.23M | 4.63M | 3.92M |
| Income Before Tax | -5.61M | 6.48M | 8.09M | 5.16M | 4.15M |
| Income Tax Expenses | 996.00K | 1.09M | 1.81M | 1.25M | 1.22M |
| Earnings from Continuing Operations | -6.60 | 5.39 | 6.28 | 3.91 | 2.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.60M | 5.39M | 6.28M | 3.91M | 2.93M |
| EBIT | -5.50M | 6.37M | 8.23M | 4.63M | 3.92M |
| EBITDA | -4.04M | 7.78M | 9.60M | 5.96M | 5.22M |
| EPS Basic | -0.08 | 0.08 | 0.09 | 0.06 | 0.04 |
| Normalized Basic EPS | -0.04 | 0.06 | 0.07 | 0.05 | 0.04 |
| EPS Diluted | -0.08 | 0.05 | 0.05 | 0.02 | 0.00 |
| Normalized Diluted EPS | -0.05 | 0.04 | 0.05 | 0.02 | 0.01 |
| Average Basic Shares Outstanding | 314.07M | 304.78M | 299.05M | 293.69M | 290.11M |
| Average Diluted Shares Outstanding | 318.21M | 343.02M | 343.43M | 335.46M | 331.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |